SCHEMBL2292116

SCHEMBL2292116

CC(C)OC(=O)c1ccccc1NC(=O)c1ccc(COc2ccccc2Cl)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.63
HPGD P15428 6/20 0.63
ALDH1A1 P00352 5/20 0.63
SMN1; SMN2 Q16637 3/20 0.63
NPC1 O15118 3/20 0.63
RAB9A P51151 3/20 0.63
SCD O00767 2/20 0.60
HDAC6 Q9UBN7 1/20 0.59
MAPT P10636 4/20 0.58
MEN1 O00255 4/20 0.54
KMT2A Q03164 4/20 0.54
PKM P14618 1/20 0.54
RXRA P19793 1/20 0.53
RXRB P28702 1/20 0.53
CASP3 P42574 2/20 0.52
SENP7 Q9BQF6 2/20 0.52
NPSR1 Q6W5P4 1/20 0.50
CTDSP1 Q9GZU7 1/20 0.49
NOD2 Q9HC29 1/20 0.49
POLB P06746 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2290679 0.89 HPGD (0.78) KDM4EHPGDALDH1A1SMN1; SMN2NPC1
SCHEMBL4206367 0.86 SMN1; SMN2 (0.53) KDM4EHPGDALDH1A1SMN1; SMN2NPC1
SCHEMBL2294806 0.79 ALDH1A1 (0.66) KDM4EHPGDALDH1A1SMN1; SMN2NPC1
SCHEMBL2292344 0.78 KDM4E (0.74) KDM4EHPGDALDH1A1SMN1; SMN2NPC1
SCHEMBL12316860 0.75 SCD (1.00) KDM4EHPGDALDH1A1SMN1; SMN2NPC1
SCHEMBL2135651 0.74 KDM4E (0.61) KDM4EALDH1A1SMN1; SMN2NPC1MAPT
SCHEMBL2221343 0.71 KDM4E (0.56) KDM4EHPGDALDH1A1NPC1RAB9A
SCHEMBL1749470 0.71 RXRA (1.00) HPGDALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL27726844 0.70 HPGD (0.63) KDM4EHPGDALDH1A1SMN1; SMN2NPC1
SCHEMBL2291513 0.70 KDM4E (0.69) KDM4EHPGDALDH1A1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101193853-B Anthranilic acid derivatives HOFFMANN LA ROCHE 2011-11-23 CN claimed
US-20090247637-A1 Novel Anthranilic Acid Derivatives DEHMLOW HENRIETTA 2009-10-01 US claimed
JP-2008546661-A 2008-12-25 JP claimed
CN-101193853-A Anthranilic acid derivatives HOFFMANN LA ROCHE (CH) 2008-06-04 CN claimed
EP-1896396-A1 ANTHRANILIC ACID DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-03-12 EP claimed
WO-2006134040-A1 ANTHRANILIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-21 WO claimed
US-20060281810-A1 Novel anthranilic acid derivatives HOFFMANN-LA ROCHE INC. 2006-12-14 US claimed
CN-101193853-B Anthranilic acid derivatives HOFFMANN LA ROCHE 2011-11-23 CN disclosed
US-7989657-B2 Anthranilic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2011-08-02 US disclosed
US-20090247637-A1 Novel Anthranilic Acid Derivatives DEHMLOW HENRIETTA 2009-10-01 US disclosed
CN-101193853-A Anthranilic acid derivatives HOFFMANN LA ROCHE (CH) 2008-06-04 CN disclosed
EP-1896396-A1 ANTHRANILIC ACID DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-03-12 EP disclosed
WO-2006134040-A1 ANTHRANILIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-21 WO disclosed
US-20060281810-A1 Novel anthranilic acid derivatives HOFFMANN-LA ROCHE INC. 2006-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281810-A1 Novel anthranilic acid derivatives GPR84, HCAR1, GPR88 KDM4E 3357/4885HPGD 922/4885ALDH1A1 529/4885
US-20090247637-A1 Novel Anthranilic Acid Derivatives GPR84, GPR88, HCAR1 KDM4E 3132/4885HPGD 1058/4885ALDH1A1 714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.